Neoleukin Therapeutics Inc (NLTX) USD0.000001
Neoleukin Therapeutics, Inc., formerly Aquinox Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is focused on the development and commercialization of computationally-designed protein therapeutics to address unmet medical needs in immuno-oncology, inflammation, and autoimmunity. Its computational platform allows it to design new de novo proteins to treat serious diseases, including cancer, inflammatory, and autoimmune disorders. Its lead program, NL-201, is a computationally-designed de novo protein therapeutic. NL-201 is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. NL-201 is designed for use as a single-agent or in combination with complementary therapeutic modalities.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.